Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

OQR200 clears proof-of-concept study
12-10-2015
SHARING OPTIONS:

VIENNA, Austria—Mid-October saw OncoQR ML announce that OQR200, its breast cancer vaccine candidate, successfully completed a proof-of-concept study in non-human primates in which it engendered the expression of very high levels of polyclonal antibodies targeting multiple epitopes on Her2/neu. These epitopes enable tumor cell killing through complement activation. OQR200 also induced polyclonal cellular immune responses to the breast cancer antigen, which activated helper T cells and cytotoxic T cells.
 
“This study with OQR200 is the third indication in which our proprietary and highly versatile S-TIR technology has shown proof of concept again in the absence of side effects,” said OncoQR CEO Christof Langer. “We are delighted that we could move OQR200 from drawing-board to preclinical proof of concept in just eight months. Our next goal is to find adequate partners that will help bring this promising breast cancer vaccine to the clinic as fast as possible.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.